You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 47 No. 2, February 1990 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Effects of Carbamazepine on Dopamine- and Serotonin-Mediated Neuroendocrine Responses

Martin Elphick, MRCPsych; Jing-Duan Yang, MD; Philip J. Cowen, MRCPsych

Arch Gen Psychiatry. 1990;47(2):135-140.


Abstract

• Neuroendocrine testing was carried out in seven male volunteers before and at the end of a 10-day course of carbamazepine (up to 700 mg daily). After carbamazepine treatment, the prolactin response to intravenous administration of the serotonin precursor tryptophan (5 g) was significantly enhanced, but there was no change in basal plasma tryptophan level or in tryptophan disposition after infusion. The prolactin response to intravenous protirelin (6.25 µg) was unaltered. Carbamazepine treatment also produced an increase in the growth hormone response to subcutaneous administration of the dopamine agonist apomorphine hydrochloride (5 µg/kg). These data suggest that carbamazepine may alter brain serotonin and dopamine function in humans. Such effects could be involved in the therapeutic properties of carbamazepine in affective disorder.



Author Affiliations

From the Oxford University Department of Psychiatry and Medical Research Council Clinical Pharmacology Unit, Littlemore Hospital, Oxford, England. Dr Elphick was Oxford Regional Health Authority Fellow in Clinical Psychopharmacology.


Footnotes

Accepted for publication June 30, 1989.

Reprint requests to Oxford University Department of Psychiatry and MRC Clinical Pharmacology Unit, Littlemore Hospital, Oxford OX4 4XN, England (Dr Cowen).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Carbamazepine Treatment in Patients Discontinuing Long-term Benzodiazepine Therapy: Effects on Withdrawal Severity and Outcome
Schweizer et al.
Arch Gen Psychiatry 1991;48:448-452.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1990 American Medical Association. All Rights Reserved.